Easterly Investment Partners LLC purchased a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,558 shares of the company’s stock, valued at approximately $208,000.
Several other hedge funds and other institutional investors also recently modified their holdings of FLGT. Rhumbline Advisers lifted its position in Fulgent Genetics by 0.9% during the second quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock valued at $1,338,000 after purchasing an additional 637 shares during the last quarter. Signaturefd LLC increased its stake in Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after acquiring an additional 1,132 shares during the last quarter. Marquette Asset Management LLC raised its position in Fulgent Genetics by 13.7% during the third quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock valued at $215,000 after purchasing an additional 1,191 shares in the last quarter. Asset Dedication LLC purchased a new stake in Fulgent Genetics during the second quarter valued at about $33,000. Finally, nVerses Capital LLC bought a new stake in Fulgent Genetics during the second quarter worth about $43,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.
Fulgent Genetics Trading Down 11.8 %
Shares of Fulgent Genetics stock opened at $19.43 on Friday. The firm has a market capitalization of $588.73 million, a PE ratio of -3.55 and a beta of 1.51. Fulgent Genetics, Inc. has a 12 month low of $18.76 and a 12 month high of $30.68. The business’s 50-day moving average price is $21.01 and its 200-day moving average price is $21.43.
Insider Buying and Selling at Fulgent Genetics
Fulgent Genetics Company Profile
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Further Reading
- Five stocks we like better than Fulgent Genetics
- Canadian Penny Stocks: Can They Make You Rich?
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.